Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508026 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,161
- Enrollment target
NCT01508026: Completed Phase 3 study, sponsored by Forest Laboratories.
NCT01508026 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 4,161 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (439% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01508026, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,161 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
Interventions
- DRUG Nebivolol and Valsartan 1
- DRUG Nebivolol and Valsartan 2
- DRUG Nebivolol and Valsartan 3
- DRUG Nebivolol 1
- DRUG Nebivolol 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,161 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01508026 record still lists
NCT01508026 is an interventional study that assigns participants to a tested intervention. Its 4,161 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (439% higher).
The record links to 0 conditions, and to 5 interventions - of which Nebivolol and Valsartan 1 is the first listed.
NCT01508026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01508026 about?
NCT01508026 is a clinical study titled "Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension". To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
What is the current status of trial NCT01508026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,161 participants. The study started on 2012-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01508026?
The interventions under investigation include: Nebivolol and Valsartan 1 (DRUG), Nebivolol and Valsartan 2 (DRUG), Nebivolol and Valsartan 3 (DRUG), Nebivolol 1 (DRUG), Nebivolol 2 (DRUG).
Who is sponsoring clinical trial NCT01508026?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01508026's enrollment target sits among peer trials
4,161 61st of 2000 higher than 1,940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06593353 · 4,165 participants · NA
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia